Introduction
Lateral spreading tumors (LST) are considered important precursors of colorectal cancer
[1]. LST were first described by Kudo as tumors with predominant spread within the mucosa
while still relatively flat [2]. In the Paris consensus of 2002, LST were defined as nonpolypoid lesions larger than 10 mm in width that typically
extend laterally and circumferentially along the colonic wall, rather than vertically
and were classified as type 0-IIa [3]. LST are distinguished based on their granular or nongranular, homogenous or nonhomogenous
appearance [1]. These lesions have been described in several studies with a wide range of definitions,
not always concordant. Therefore, it is of paramount importance to establish an unambiguous
and consensual definition for these lesions.
LST tend to preferentially spread superficially along the colonic wall rather than
invading the submucosal layer and endoscopic resection can be effectively used as
a minimally invasive treatment for the majority [4]. The flat morphology and potentially large dimensions of LST may render complete
resection challenging [4]. The most common treatment approach for LST is endoscopic mucosal resection (EMR).
However, en-bloc resection is usually restricted to lesions of less than 20 mm diameter.
Piecemeal EMR of larger lesions is usually safe, but may hinder histologic assessment
and lead to an increased risk of local recurrence. Endoscopic submucosal dissection
(ESD) may overcome this problem, allowing dissection of larger lesions in one piece,
although the procedure is technically more difficult, much more time-consuming, mandates
multiday hospital admission and has an increased risk of perforation [5]. The majority of colorectal superficial lesions can be removed in a curative way
by polypectomy or EMR; nevertheless, ESD should be considered for the removal of colorectal
lesions with high suspicion of limited submucosal invasion, including those with depressed
morphology or irregular/nongranular surface pattern, particularly in lesions larger
than 20 mm [6].
Some recent meta-analyses have addressed endoscopic treatment outcomes of large non-pedunculated
colorectal lesions and large colorectal polyps [7]
[8]
[9]. However, there are no published systematic reviews or meta-analyses focusing exclusively
on LST.
In this systematic review and meta-analysis, the authors aimed to evaluate the efficacy
and safety outcomes of endoscopic treatment of colorectal LST. Since many authors
include purely sessile lesions in the LST group, it was also intended to study the
clinical relevance of distinguishing LST from large sessile colorectal lesions.
Methods
A systematic review was conducted according to the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement [10]. The current systematic review was structured through the following PICO framework,
addressing patients with LST, submitted to ESD/EMR/TEMS and evaluating the following
outcomes: en-bloc/piecemeal, complete endoscopic resection, R0 and curative resections,
adverse events and recurrence.
Eligibility criteria
All clinical studies published before June 15, 2016 in which colorectal LST were treated
with endoscopic resection (EMR and ESD) and/or transanal minimally invasive surgery
were considered. Only studies that reported at least one of the main treatment outcomes
(en-bloc/piecemeal resection; complete endoscopic resection; R0 resection; curative
resection; AEs or recurrence), were eligible for inclusion. Prospective and retrospective
cohort studies, case-control studies and therapeutic clinical trials were included.
Manuscripts were excluded if they: (1) included sessile lesions (Paris 0-Is) and LST
in the same group without a sub-analysis for LST treatment outcome; (2) included fewer
than 20 LST (3) were animal or review studies; or (4) were non-English studies.
If there was suspicion of patient overlap between studies, only the study with the
largest patient cohort for each of the outcomes was included.
Definitions
En-bloc resection was defined as resection of the lesion in one single piece and piecemeal
resection as resection in more than one fragment.
Complete endoscopic resection was defined as the perception of the endoscopist that
the lesion had been completely removed during endoscopy.
The resection was considered as R0 when histopathological examination confirmed free
vertical and lateral margins, as R1 if the resection margins were involved or as Rx
if the lateral or deep margins couldn’t be evaluated due to piecemeal resection or
coagulation effects.
Local recurrence implies that the patients were followed up for at least one colonoscopy
after the index procedure and was defined as the finding of dysplastic tissue with
histopathological confirmation detected at the site of previous endoscopic treatment.
Resection was considered curative for adenomatous lesions or intramucosal carcinoma
if R0 resection was achieved or if there was no recurrence at the end of follow up. For
minimally invasive adenocarcinoma (sm1 invasion < 1000 µm) resection was considered
curative for well-differentiated tumors if R0 resection was achieved and there was
no lymphovascular or perineural invasion.
Bleeding was classified into two subtypes: immediate and delayed. Immediate bleeding
was defined as active bleeding that developed during the procedure. Delayed bleeding
was defined as melena or bloody stools that occurred after completion of endoscopic
resection. Bleeding was further classified as minor (when hemostasis required endoscopic
procedures – hemoclip application/injection therapy, without a blood transfusion)
or massive (when requiring blood transfusion and/or surgery) [11]
[12]
[13]
[14]
[15]. Bleeding during the resection procedure that was stopped spontaneously or with
hemostatic forceps was not considered to be a complication. [5] In most cases, large visible exposed vessels or bleeding points were coagulated
using hemostatic forceps and any remaining vessels visible after completed resection
were also coagulated routinely to prevent delayed bleeding.
Perforation was immediate (diagnosed by endoscopic evidence of a definite mural defect
with the visualization of an intraperitoneal organ or peritoneal/fat tissue) or delayed
(diagnosed after a finished endoscopic resection by presence of free air on abdominal
plain radiograph or during a computed tomogram) [11]
[12]
[14]
[15].
Search strategy
Relevant studies were identified in three electronic databases (MEDLINE through PubMed;
ISI Web of Knowledge and Cochrane Central Register of Controlled Trials). The search
was performed using the following query for PubMed: (polyp OR tumor OR tumour OR tumors
OR lesion OR neoplasm OR adenoma) AND (non-pedunculated OR large OR flat OR “lateral
spreading”; OR “laterally spreading”; OR LSL OR LST) AND (colon OR rectum OR colorectal
OR colorectal OR colonic OR rectal) AND (endoscopic AND (resection OR EMR OR ER OR
mucosectomy OR endoscopic submucosal dissection OR ESD OR polypectomy OR transanal
endoscopic microsurgery OR TEMS OR TEM OR TAMIS OR “transanal surgery”). The search
terms for other databases were adapted from this query. Additional studies were identified
by checking the list of references of all included studies and also review articles
on this topic. The last search was performed on June 15, 2016.
Study selection
After removal of duplicates, two authors (PR, SB) independently screened all titles
and abstracts for relevance. The full text of selected relevant studies was then evaluated
by the same two researchers according to the inclusion criteria described above. A
third author (MDR) intervened in case of disagreement.
Quality evaluation and data extraction
Data extraction was performed by PR, SB and HA. Another two reviewers (MDR and MJB)
independently checked the extracted data and disagreements were solved by consensus.
From each paper the following data were collected: (1) country; (2) publication year;
(3) setting (single-center/multicenter); (4) enrollment period; (5) study design (prospective/retrospective);
(6) type of resection techniques (EMR/ESD/TEMS); (7) operator (single/multiple; experienced/non-experienced);
(8) definition of LST; (9) number of LST; (10) number of patients with LST; (11) mean/median
age of the patients with LST; (12) gender distribution; (13) morphology of LST and
subtypes (LSTG/LSTNG and LSTGH/LSTGM/LSTNGF/LSTNGPD); (14) mean size of LST; (15)
size distribution (number of ≥ 10 mm/≥ 20 mm/≥ 30 mm/≥ 40 mm); (16) site distribution
(proximal/distal); (17) type of resection (en-bloc/piecemeal); (18) rate of complete
endoscopic resection; (19) histology (R0 and curative resection); (20) rate of AE
(bleeding, perforation, death, other); (21) average follow-up period (months); (22)
rate of recurrence; (23) treatment of recurrence; and (24) rate of surgery (for unsuccessful
complete resection, for non-curative resection, for AE or for recurrence).In some
articles, added additional data provided by the authors were added.
Quality evaluation was performed by PR and HA using the Newcastle-Ottawa scale.
Data synthesis and statistical analysis
Raw data for each outcome (number of events and total) were collected allowing calculation
of outcome prevalence and standard error. For meta-analysis, as most of the studies
report prevalence rates between 0 % and 100 % (depending on the evaluated outcome),
the double arcsine transformation (Freeman-Tukey) was used to adjust for variance.
Double arcsine transformed proportions were then used for calculation of pooled proportions
and were back-transformed for results presentation to allow easier interpretation.
Meta-analysis was performed with MetaXL and Open Meta-analyst using a random-effect
model and heterogeneity was evaluated with Cochran’s Q test and I2, a measure of inconsistency. A subgroup analysis was planned according to the resection
method used (EMR or ESD). Sensitivity analysis was performed when substantial heterogeneity
was detected. Publication bias was assessed visually with funnel plot for the primary
outcome.
Results
Study selection
A total of 2819 studies were identified by the searches in PubMed (1666), ISI (1023)
and Cochrane Register of Controlled Trials (130). After screening titles and abstracts,
873 studies were found to be eligible. After full-text analysis, 824 studies were
excluded (812 did not fill the inclusion criteria; 10 had risk of patient overlap;
two due to conflicting data) while 49 studies were included. A flow chart of the selection
process is shown in [Fig. 1].
Fig. 1 Flow chart of the selection of studies eligible for data extraction and analysis.
Study characteristics
The main characteristics of the included studies are listed in [Table 1]. Most of the studies were single-center (43, 87.8 %), and six (12.2 %) were multicenter.
The majority (42, 85.7 %) were retrospective. Sixteen studies evaluated EMR, including
two studies of cap-assisted EMR and two studies including underwater EMR (one them
for recurrent LST); 29 studies reported one or more outcomes for ESD; four studies
reported outcomes for both techniques. A total of 27 studies included exclusively
laterally spreading tumors, while a sub-analysis for LST was available in the other
22 studies.
Table 1
The main characteristics of the included studies.
|
Period of enrollment, years
|
Number of LST
|
Size of LST included, mm
|
Technical modifications
|
Quality[1]
|
|
EMR
|
|
Prospective, multicenter
|
|
Australia
|
|
Burgess NG, 2014 [69]
|
2008 – 2013
|
873
|
≥ 20
|
|
7
|
|
Moss A, 2015
|
2008 – 2012
|
747
|
≥ 20
|
|
6
|
|
Italy
|
|
Conio M, 2010 [16]
|
2000 – 2007
|
136
|
≥ 20
|
Cap EMR
|
6
|
|
Greece
|
|
Fasoulas K, 2012 [18]
|
2005 – 2010
|
49
|
≥ 30
|
|
RCT
|
|
Czech
|
|
Urban O, 2008 [4]
|
2002 – 2006
|
138
|
> 10
|
|
6
|
|
Prospective, single-center
|
|
Germany
|
|
Belle S, 2012 [25]
|
2006 – 2007
|
70
|
> 12
|
STEP EMR
|
6
|
|
Retrospective, single center
|
|
Japan
|
|
Yoshikane H, 1999 [17]
|
1996 – 1998
|
23
|
NR
|
Cap EMR
|
8
|
|
Uraoka T, 2005 [14]
|
1998 – 2003
|
223
|
≤ 30
|
|
6
|
|
Tanaka,2001 [70]
|
NR
|
120
|
≥ 20
|
|
6
|
|
Tamura S, 2004 [71]
|
1989 – 2002
|
67
|
NR
|
|
6
|
|
China
|
|
Huang Y, 2009 [38]
|
2000 – 2007
|
111
|
≥ 10
|
|
6
|
|
Taiwan
|
|
Su MY, 2008 [72]
|
1999 – 2005
|
201
|
> 10
|
|
6
|
|
UK
|
|
Hurlstone DP, 2004 [73]
|
1999 – 2003
|
82
|
≥ 10
|
|
6
|
|
Arebi N, 2007 [27]
|
1997 – 2005
|
48
|
≥ 20
|
|
6
|
|
United States
|
|
Kim HG, 2014 [26]
|
2009 – 2014
|
80
|
LST ≥ 20
|
Underwater EMR
|
7
|
|
Binmoller KF, 2015 [19]
|
NR
|
53
|
> 20 and < 40
|
Underwater EMR
|
5
|
|
ESD
|
|
Prospective, single-center
|
|
Japan
|
|
Ritsuno H, 2014 [53]
|
2010 – 2011
|
50
|
> 20
|
ESD S-O clip traction
|
RCT
|
|
Retrospective, multicenter
|
|
Japan
|
|
Mizushima T, 2015 [54]
|
2011 – 2013
|
113
|
NR
|
|
6
|
|
Retrospective, single center
|
|
Japan
|
|
Uraoka T, 2010 [56]
|
2006 – 2008
|
37
|
LSTG ≥ 30 and LSTNG ≥ 20
|
|
8
|
|
Okamoto K, 2012 [59]
|
2010 – 2011
|
30
|
> 20 LSTNG;
> 30 LSTG
|
Traction vs. no traction
|
7
|
|
Suzuki S, 2014 [13]
|
2009 – 2013
|
290
|
NR
|
|
6
|
|
Niimi K, 2010 [11]
|
2000 – 2008
|
245
|
NR
|
|
6
|
|
Nishiyama H, 2010 [12]
|
2002 – 2008
|
204
|
> 20
|
|
6
|
|
Hotta K, 2012 [58]
|
2000 – 2010
|
201
|
NR
|
|
6
|
|
Hisabe T, 2012 [57]
|
2003 – 2011
|
162
|
NR
|
|
6
|
|
Sakamoto T, 2014 [49]
|
2005 – 2012
|
139
|
> 20
|
|
6
|
|
Nawata Y, 2014 [61]
|
2010 – 2013
|
137
|
18 – 123
|
|
6
|
|
Toyonaga T, 2010 [55]
|
2009 – 2010
|
132
|
NR
|
|
6
|
|
Makino T, 2015 [62]
|
2009 – 2013
|
58
|
> 10
|
|
5
|
|
Okamoto K, 2013 [60]
|
2010 – 2012
|
30
|
28 – 45
|
M2-SB
|
5
|
|
Korea
|
|
|
|
|
|
|
Bae JH, 2015 [15]
|
2007 – 2014
|
153
|
≥ 30
|
ESD and ESD with snaring
|
8
|
|
EJ Lee 2011 [63]
|
2006 – 2010
|
358
|
≥ 20
|
|
7
|
|
Hong MJ, 2015 [65]
|
2010 – 2013
|
113
|
> 20
|
|
7
|
|
Jung DH, 2015 [66]
|
2009 – 2014
|
163
|
NR (subgroup ≥ 100)
|
|
6
|
|
Yoon JY, 2012 [64]
|
2008 – 2011
|
101
|
≥ 10
|
|
6
|
|
Kim ES, 2011 [23]
|
2007 – 2009
|
81
|
≥ 10
|
|
6
|
|
China
|
|
Xu MD, 2013 [41]
|
2008 – 2011
|
137
|
≥ 20
|
|
8
|
|
Cong ZJ, 2015 [36]
|
2003 – 2007
|
177
|
≥ 30
|
|
7
|
|
Zhou PH, 2009 [67]
|
2006 – 2007
|
74
|
≥ 20
|
|
6
|
|
Tang XW, 2016 [30]
|
2010 – 2014
|
36
|
≥ 40
|
|
5
|
|
Turkey
|
|
Hulagu S, 2013 [20]
|
2006 – 2011
|
44
|
≥ 20
|
|
5
|
|
Austria
|
|
Berr F, 2014 [24]
|
2009 – 2012
|
39
|
≥ 20
|
|
5
|
|
UK
|
|
|
|
|
|
|
Hurlstone DP, 2007 [22]
|
2004 – 2006
|
28
|
≥ 20
|
|
6
|
|
Germany
|
|
Probst A, 2012 [5]
|
2004 – 2011
|
74
|
> 15
|
|
9
|
|
Italy
|
|
Repici A, 2013 [68]
|
2010 – 2011
|
40
|
33 – 80
|
|
6
|
|
ESD vs. EMR
|
|
|
|
|
|
|
Retrospective, single center
|
|
Japan
|
|
Iizuka H,2009 [21]
|
2000 – 2004
|
70
|
≥ 20
|
|
7
|
|
Terasaki, 2011 [74]
|
2006 – 2009
|
267
|
> 20
|
ESD/hybridESD vs. EMR/EMRP
|
6
|
|
India
|
|
Tajika M, 2011 [75]
|
1995 – 2009
|
106
|
> 20
|
|
7
|
|
UK
|
|
Hurlstone DP, 2006 [52]
|
1999 – 2004
|
20
|
16 – 58
|
Salvage EMR/ESD
|
6
|
1 Quality evaluation using Newcastle-Ottawa scale. NR-not reported.
Inclusion criteria regarding lesion size varied between the studies: lesions ≥ 10 mm
– 7 studies; ≥ 12 mm – 1 study; ≥ 15 mm – 1 study; 20 studies included lesions ≥ 20 mm
(one of them ≤ 40 mm); 3 studies included lesions ≥ 30 mm and one ≥ 40 mm; 2 studies
included LST-NG ≥ 20 mm and LST-G ≥ 30 mm; one study included lesions ≤ 30 mm; the
other studies did not specify inclusion criteria based on size.
En-bloc/piecemeal resection was reported in 12 EMR and 17 ESD studies. Complete endoscopic
resection according to our definition was available in 20 studies (8 EMR and 12 ESD).
R0 rates were assessed in three EMR and 14 ESD studies, while data on the recurrence
was given in 15 EMR and 15 ESD studies. We could extrapolate curative resection according
to our criteria in six EMR and eight ESD studies. Twelve studies reported global AE
rate for EMR; 13 reported perforation and 14 bleeding. The same information was available
for ESD in 21, 25 and 19 studies, respectively.
Information regarding surgical intervention was available in 16 EMR studies (12 for
surgery of recurrence; 14 for AE and 12 for incomplete/non-curative resection) and
21 ESD studies (11 for recurrence, 19 for AEs and 10 for incomplete/non-curative resection).
En-bloc resection
Overall, pooled en-bloc resection rate was 75.6 % (95 % CI 60.4 %-88.2 %, I2 = 99 %), being significantly higher with ESD (93.7 %, 95 % CI 89.3 – 95.6 %) – versus
EMR (37.7 %, 95 % CI 23.0 % – 53.5 %) ([Fig. 2a]). Conio M. et al. [16] applied the cap-assisted EMR technique in all of the lesions (≥ 20 mm) which explains
the 0 % en-bloc resection in this study. The study by Yoshikane H. et al. [17] also evaluated cap-assisted EMR but included lesions ≥ 10 mm, allowing 65.2 % en-bloc
resection. The lower en-bloc rate in Fasoulas K. et al. [18], is explained by the inclusion of larger lesions ( ≥ 30 mm). In contrast, Binmoller
K.F. et al. [19], resected 55 % of the lesions (20 – 40 mm) en-bloc using the underwater EMR technique.
The two studies with lower ESD en-bloc rate were Hulagu S. et al. and Iizuka H. et
al. [20]
[21]. Hulagu S. et al. [20], justified their lower rate of en-bloc resection with the higher rate of partial
prior endoscopic resection (polypectomy) and scar tissue formation. The high rate
of deep submucosal cancer may have precluded better results in the Lizuka et al. study
[21]. En-bloc resection rates were not significantly different for LST-G and LST-NG for
both ESD and EMR (ESD: 11 studies, OR 0.837 95 % CI 0.534 – 1.312, I2 = 0 %; EMR: 4 studies, OR 0.529 95 % CI 0.410 – 0.683, I2 = 25 %).
Fig. 2a Rate of en-bloc resection by technique.
Fig. 2b Rate of complete endoscopic resection by technique.
Fig. 2c Rate of complete endoscopic resection by type of lesion.
Fig. 2d Rate of curative resection according to technique.
Fig. 2e Submucosal invasion by technique.
Fig. 2f Recurrence rate by technique.
The rate of en-bloc resection in EMR studies was not significantly different in studies
including lesions > 10 mm and > 20 mm; only two studies using the 30-mm threshold
were found and the rate of en-bloc resection was significantly higher in the Study
including lesions < 30 mm (53,8 % 95 % CI 47.2 – 60.3 % versus 22.4 % 95 % CI 11.7 – 35.3 %).
The rate of ESD en-bloc resection was not influenced by the size of the lesions included,
being > 90 % in all subgroups ( > 20 mm: 6 studies, 92.8 % 95 % CI 86.8 – 97.5 %; > 30
mm: 4 studies, 91.9 % 95 % CI 83.9 – 98.1 %; > 40 mm: 1 study, > 100 mm: 1 study,
93.3 95 % CI 88 – 96.7 %; not reported: 5 studies, 93.5 % 95 % CI 85.2 – 99.5 %).
In a subgroup analysis, according to the size of included lesions, the rate of en-bloc
resection was significantly higher in ESD studies whether they included lesions > 20 mm
or > 30 mm.
Complete resection and R0 resection
Complete endoscopic resection by endoscopist opinion was achieved in 98.6 % (95 %
CI 97.6 – 99.4 %, I2 = 58 %), being similar with EMR and ESD ([Fig. 2b]). Pooled R0 resection was 79.2 % (95 % 68.3 – 88.4 %, I2 = 79.2), being significantly higher with ESD (86.4 % 95 % CI 79.5 – 91.7 % vs. EMR
36.2 % 95 % CI 31.2 – 41.8 %), Once again the study by Lizuka, 2009, showed lower
ESD complete endoscopic and R0 resection rates, possibly because of the high incidence
of deep submucosal invasion [21]. In the Hurlstone ESD study [22], a low R0 rate (67,9 %) is in correlation with a low en-bloc rate (78,6 % – includes
non-LST lesions).
There were no statistically significant differences between R0 resection for LST-G
and LST-NG (OR 1.082 CI 0.770 – 1.519, I2 0 %). R0 resection was achieved in 673 /763 (83.5 %) of LST-G and 347 /417 (83.2 %)
of LST-NG ([Fig. 2c]).
Curative resection
Overall, endoscopic resection of LST was curative in 1685/1895 (13 studies, pooled
curative resection 90 %, 95 % CI 86.6 – 92.9 %, I2 = 79 %). Subgroup analysis according to the technique used showed significantly higher
curative resection rates with ESD (93.6 % 95 % CI 91.3 – 95.5 %, versus 84 % 95 %
CI 78.1 – 89.3 % with EMR) ([Fig. 2d]). It is worth highlighting the study by Fasoulas et al. [18], with the lowest curative resection rates among the EMR studies that included larger
lesions (≥ 30 mm).
Submucosal invasion
Prevalence of cancer was similar between the EMR and the ESD series, despite the trend
towards more submucosal invasion in the ESD series (EMR 5.6 % 95 % CI 2.0 – 10.2 %
versus ESD 11 % 95 % CI 5.9 – 17.0 %) ([Fig. 2e]). If we exclude the outliers (studies with a prevalence of submucosal invasion > 20 %),
(Terasaki EMR; Uraoka T; Terasaki ESD, Yoon JY) the difference is still not significant
(EMR 4.1 % 95 % CI 2.3 – 6.2 % versus ESD 5.8 % 95 % CI 4.4 – 9.6 %). LST-G presented
less submucosal invasion (39/503) when compared to LST-NG (OR 0.47 95 % CI 0.29 – 0.74).
Adverse events
Resection of LSTs was associated with a pooled incidence of overall AEs of 9.2 % (7.2 – 11.5 %).
No significant differences between EMR and ESD were found ([Fig. 3a]).
Fig. 3a Adverse events. Overall adverse events by technique.
Fig. 3b Adverse events. Perforation by technique.
Fig. 3c Adverse events. Bleeding rate by technique.
Overall, pooled perforation rate was 4.1 % (95 % CI 2.7 – 5.6 %, I2 = 84 %). However, ESD was associated with a significantly higher perforation risk
(pooled incidence 5.9 % 95 % CI 4.3 – 7.9 %, versus EMR 1.2 % 95 % CI 0.5 – 2.3 %)
([Fig. 3b]). The studies by Kim [23] and Berr [24] registered the larger number of perforations. The latter study evaluated the untutored
learning of ESD in a series of 50 lesions including 33 colorectal LST and 15.2 % of
the colorectal procedures were complicated with perforation. If this study is excluded
the perforation rate is 5.7 %.
On the other hand, pooled bleeding rate was 5.3 % (95 % CI 3.6 – 7.2 %) and was significantly
more frequent with EMR (9.6 % 95 % CI 6.5 – 13.2 %; versus ESD 2.8 % 95 % CI 1.9 – 4.0 %)
([Fig. 3c]). Bleeding rate was particularly high in the study by Belle et al. [25], in which 25/66 patients required hemostasis with clips. If this atypical study
is excluded, the bleeding rate is 4.8 % (95 % CI 3.4 %-6.5 %) and remains significantly
higher with EMR.
If we only consider major bleeding there were no statistically significant differences
between both techniques (EMR 0.2 % 95 % CI 0 – 0.04 % versus ESD 0.4 % 95 % CI 0.1 – 0.7 %).
Immediate minor bleeding was significantly less frequent for ESD (0.5 % 95 % CI 0.1 – 1.0 %
versus EMR: 7.7 % 95 % CI 1.5 – 15.9 %). No differences were found between EMR and
ESD for delayed major or minor bleeding.
Coagulation syndrome was evaluated in five studies including 718 patients (3 EMR,
1 EMR&ESD and 1 ESD studies) and pooled rate was 3.1 % (95 % CI 0.3 – 8.0 %, I2 = 86 %).
One patient died following EMR due to complications of acute myocardial infarction
[4]. Pooled procedure-related mortality was 0.1 % (95 % CI 0.0 – 0.3 %, I2 = 0 %).
Between both subtypes of LST there were no differences in perforation or bleeding
rates. In LST-G, perforation occurred in 52/906 (5.74 %) while in LST-NG it occurred
in 20/446 (4.48 %) (OR 1.072, 95 % CI 0.497 – 2.310, I2 = 36.94 %). Bleeding was more frequent with LST-G (26 /585 – 4.44 %) compared with
LST-NG (11 /424 – 2.59 %) (OR 2.460, 95 % CI 0.476 – 12.729, I2 = 75.05 %).
Recurrence
Overall, recurrence occurred in 5.5 % (95 % CI 3.0 – 8.6 %) being significantly more
frequent with EMR (12.6 % 95 % CI 9.1 – 16.6 %) vs. ESD (1.1 % 95 % CI 0.3 – 2.5 %).
However, the majority of the recurrences were amenable to successful endoscopic treatment
(87.7 %, 95 % CI 81.1 – 93.1 %). The timing of endoscopic surveillance was heterogeneous
between the studies which may have affected the rate of early recurrence. Mean follow-up
ranged from 9.2 to 60.8 months.
The retrospective study from Kim et al. evaluated the efficacy of underwater versus
conventional EMR for the treatment of recurrence after piecemeal resection of LST
[26]. Underwater EMR was successful in 18/20 patients and conventional EMR was successful
in only 20/33 [26]. Two EMR studies demonstrated the highest recurrence rates, Arebi N. et al. [27] (40.9 %, 95 % CI 26.7 – 55.9 %) and Fasoulas et al. [18] (27.3 %, 95 % CI 15.0 – 41.5 %). The latter, probably because larger lesions (≥ 30 mm)
were included with only 22.4 % removed en-bloc [18].
Surgery rates
Overall, LSTs submitted to endoscopic resection led to surgery in 2.7 % (95 % CI 1.8 – 3.8 %),
without significant differences in surgery rates according to the endoscopic resection
technique despite a trend to higher surgery rates with EMR ([Fig. 4a]). Concerning the reasons for surgery:
-
33 studies involving 3857 patients reported 12 surgeries due to AEs (pooled rate was
0.5 %, 95 % CI 0.3 – 0.7 %, I2 = 0 %); there was no difference in surgery due to AEs between the ESD and the EMR
group.
-
23 studies involving 2257 patients reported eight surgeries due to recurrences detected
during follow up (pooled rate was 0.5 %, 95 % CI 0.2 – 0.8 %, I2 = 0 %) ([Fig. 4b]). There was no significant difference between the two techniques.
-
21 studies involving 2799 lesions reported 125 surgeries due to incomplete/non-curative
resection (pooled rate was 4.3 %, 95 % CI 3.3 – 5.5 %, I2 = 44 %). No significant difference between EMR and ESD was found (pooled rate EMR
was 3.9 %, 95 % CI 2.5 – 5.5 %, I2 = 55 % vs. pooled rate ESD was 4.6 %, 95 % CI 3.0 – 6.3 %, I2 = 30 %) ( [Fig. 4c]).
Fig. 4a Follow-up and surgery. Overall surgery rate by technique.
Fig. 4b Follow-up and surgery. Rate of surgery due to recurrence by technique.
Fig. 4c Follow-up and surgery. Rate of surgery due to incomplete resection by technique.
Publication bias
Visual inspection of the funnel plot and doi plot analysis (LFK index 0.14 – absence
of asymmetry) suggests the absence of publication bias for the primary endpoint (curative
resection).
Discussion
According to our analysis, both EMR and ESD were effective and safe with a low risk
of procedure-related morbidity and rare mortality. Cure from the primary intervention
was more frequently achieved with ESD (93.6 % vs. 84 % for EMR) with higher recurrence
among patients submitted to EMR (12.6 % vs. 1.1 % for ESD) but the endoscopic treatment
of recurrence was highly effective (87.7 %). We found no difference in surgery between
both techniques due to incomplete endoscopic/histologic resection or recurrence.
The rate of AEs was low and most complications could be managed endoscopically, as
shown by a surgery rate for AEs of 0.3 %. Clearly both techniques are very safe. Risk
of perforation was significantly higher for ESD (5.9 % vs. 1.2 % for EMR) and risk
of bleeding was statistically greater with EMR (9.6 % vs. 2.8 % for ESD), but major
bleeding and delayed bleeding rates were similar for both techniques.
In this meta-analysis, we exclusively included LSTs according to the accepted definition
of flat laterally spreading lesions > than 10 mm. These lesions often cannot be reliably
excised en-bloc by conventional snare polypectomy, especially if larger than 20 mm.
In this study, we have examined the interface between the two available therapeutic
techniques of EMR and ESD. This study evaluates outcomes in a defined, discrete and
well characterized subgroup of large colorectal neoplasms and is substantially different
from previous work [7]
[28]
[29].
Hassan et al. assessed efficacy and safety of endoscopic resection of large colorectal
lesions (> 20 mm) [7]. Broadly classified as sessile, pedunculated or non-polypoid, in this study, all
types of tissue resection techniques including conventional polypectomy (26 %) were
included. Consequently, there is relative data heterogeneity and the results are thus
hard to interpret. Detailed morphological features are not described and thus the
influence of morphology outcomes was not evaluated. Paris classification and surface
morphology (granular/non-granular) were not assessed. Endoscopic tissue resection
has continuously developed and improved over time, particularly in the last 10 years.
Hassan et al. included eight studies before 2000 which may have substantially influenced
the outcomes of the analysis [7]. The main outcome of this study was the rate of subsequent surgery for all reasons.
The surgery rate was 8.3 %, among these 0.5 % due to AEs and 7.8 % due to non-curative
resections. In our study, of LSTs excised by EMR or ESD, the rate of post-endoscopic
resection surgery was 2.7 %. In pooled rate analysis of our data, surgery due to non-curative
endoscopic resection, AEs and recurrence were 4.2 %, 0.5 % and 0.5 % respectively.
Overall AEs were 9.2 %, perforations accounted for 4.1 % and bleeding was 5.3 %.
Overall the recurrence rate in our study was 5.5 % which is lower than reported in
other studies. Hassan et al. reported an overall recurrence rate of 13.8 %, while
the recurrence rate post-EMR versus post-ESD in both studies was 12.7 % vs. 1.1 %
and 15 % vs. 1 %, respectively [7]. Belderbos et al. evaluated 33 EMR (> 10 mm) studies for recurrence rate [28]. The overall recurrence rate was as high as 15 %, with 3 % for en-bloc resections
and 22 % for piecemeal resections. Treatment of recurrence was successful in 91.4 %
of the lesions, after a median of 1.2 endoscopic retreatments. Piecemeal resection
was the only risk factor that was clearly associated with recurrence in multivariable
analysis [28].
In ESD treatment, Puli and Hassan both reported en-bloc rates of 85 % and 50 %, respectively
[7]
[29]. These rates are lower than our data (93.7 % en-bloc). In our analysis, according
to our predefined and more stringent criteria most of the ESD studies were from the
east.
Mortality related to endoscopic procedures was similar (0.08 % in Hassan C. et al.
vs. 0.10 % in our data) [7].
In this meta-analysis, we included mainly observational cohort studies and case-control
studies, most of them either single-center or retrospective. However, to mitigate
the risk of bias, we used the Newcastle-Ottawa Scale for assessing the quality of
nonrandomized studies.
Limitations
Our search did not retrieve any results on minimally invasive transanal surgery (transanal
endoscopic microsurgery), mostly because in the studies involving these techniques
a morphologic classification was not applied. It would be advisable to apply this
classification in future studies evaluating these techniques.
One of the major limitations of our work is the heterogeneous classification of lesions
applied in the different papers. Many studies on the endoscopic treatment of large
(> 10 mm) Paris 0-IIa lesions (as well as 0-IIa + c or 0-IIa + Is) were excluded because
the denomination LST was not present. Most, if not all these lesions probably correspond
to LST. Several studies that included LST along with other polypoid and non-polypoid
lesions that didn’t make a subanalysis of LST subgroup were also excluded. The other
major limitation refers to the fact that most of the studies are either single-center
or retrospective.
Data are scarce to compare the outcomes for the different LST subtypes (LST-GH, LST-GM,
LST-NGF and LST-NGPD). For many non-Japanese studies, chromoendoscopy is not routinely
applied, hence this may affect the accuracy of the morphological diagnosis of LST
(especially LST-NG-PD) and evaluation of residual neoplasm in resection margin. The
histological characteristics were usually not analyzed and they can play a major role
in the outcomes, as more advanced histological lesions are related with lower curative
resection.
The duration from endoscopic treatment to surveillance examination was heterogeneous
between the studies and may have affected the rate of early recurrence.
Conclusion
A wide range of definitions was applied to describe LST, not always concordant. Therefore,
it is of paramount importance to establish an unambiguous and consensus definition
for these lesions.
Definitions are nearly unanimous in describing LST as flat or non-polypoid lesions
that extend laterally (or horizontally, or superficially) and circumferentially, rather
than vertically along the colonic wall [20]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38].
Although some studies consider a minimum of 20 mm of diameter to fit in this classification
[39]
[40]. Most of the authors include lesions beyond 10 mm in this group [4]
[20]
[30]
[32]
[34]
[35]
[36]
[37]
[38]
[41]
[42]
[43]
[44]. Another contention appears when establishing the maximum allowed vertical growth.
Most commonly laterally spreading lesions within the fully inflated colon are described
as lesions with height of less than half the diameter [45]. Bae JH et al. [15], defined LST as lesions with less than 2.5 mm in height.
Some authors make no distinction between sessile lesions and LST [46], while many other authors, despite making this distinction, analyze them in the
same group of large sessile and laterally spreading lesions [47]
[48]. The difference between large sessile and laterally spreading tumors can actually
be difficult and subjective. The Paris endoscopic classification of superficial neoplastic
lesions of 2002 states that slightly elevated lesions are easily misclassified as
sessile (polypoid subtype) at endoscopy. This distinction is more reliable on pathologic
examination of an operative specimen, in which it is possible to compare the height
of the lesion with the full thickness of the normal mucosa, although this also has
limitations due to specimen shrinkage with fixation.
When applying the Paris classification into the LST sub-classification, most authors
include IIa, IIa + Is and IIa + IIc lesions in this group [5]
[24]
[49]. Some studies also classify these lesions as IIb [18]
[24] and IIa + IIb [19]. Berr F et al. classified LST-GH as IIa, LST-GM as IIa + Is, LST-NGF as IIa or IIb
and LST-NGPD as IIa + c [24]. However, some authors have considered LST-NG as IIa and LST-G as IIa + Is lesions
[49]
[50].
Alternatively, some studies differentiate an LST group from a Paris II group (including
IIa lesions), with both groups having large > 10 mm lesions [22]
[51]
[52].
In the Paris consensus of 2002 “lateral spreading type” lesions were included in type
0-IIa [3].
The authors suggest the following criteria to classify a lesion as LST:
-
Flat or non-polypoid lesions that extend laterally and circumferentially rather than
vertically along the colonic wall, with a minimum diameter of 10 mm.
-
Laterally spreading lesions shall be slightly elevated or at least have a real flat
component (0-IIa). Pure sessile lesions (Paris 0-Is) shall not be classified as LST.
To differentiate LST from sessile lesions the height of these lesions must be less
than half of its diameter.
-
LST shall be classified into LST-G, which includes LST-GH (which corresponds to Paris
0-IIa lesions) and LST-GM (Paris 0-IIa + Is lesions) and LST-NG, which includes LST-NGF
(Paris 0-IIa) and LST-NGPD (Paris 0-IIa + c).